natgillin/translations-raw huggingface dataset:
Do not take medicines known to cause neutropenia or agranulocytosis (see “Do not take Deferiprone Lipomed”).
Nemojte uzimati lijekove za koje se zna da uzrokuju neutropeniju ili agranulocitozu (pogledajte dio „Nemojte uzimati Deferipron Lipomed“).
Deferiprone and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p>0.05).
Deferipron i deferoksamin bili su jednaki u poboljšanju stabilizacije ili redukcije opterećenja tijela željezom unatoč kontinuiranoj primjeni željeza u transfuzijama u ovih bolesnika (nije bilo razlike u udjelu bolesnika s negativnim trendom feritina u serumu između dviju liječenih skupina dobivene regresijskom analizom; p >0,05).
Data from the pooled safety database from clinical trials (1343 patient-years exposure to deferiprone monotherapy and 244 patient-years exposure to deferiprone and deferoxamine) showed statistically significant (p<0.05) differences in the incidence of adverse reactions based on System Organ Class for “Cardiac disorders”, “Musculoskeletal and connective tissue disorders” and “Renal and urinary disorders”.
Podatci iz objedinjene baze podataka o sigurnosti primjene dobivenih iz kliničkih ispitivanja (1343 bolesnik-godina izloženosti monoterapiji deferipronom i 244 bolesnik-godina izloženosti deferipronu i deferoksaminu) pokazali su statistički značajne (p<0,05) razlike u incidenciji nuspojava koje se temelje na klasifikaciji organskih sustava za „srčane poremećaje”, „poremećaje mišićnokoštanog sustava i vezivnog tkiva” te „poremećaja bubrega i mokraćnog sustava”.
The observed incidence of the less severe form of neutropenia (neutrophils <1.5 x 109/l) is 4.9% (2.5 cases per 100 patient-years).
Opažena incidencija manje teškog oblika neutropenije (neutrofili <1,5 x 109/l) je 4,9% (2,5 slučajeva na 100 bolesnik-godina).
Deferiprone has been shown to cause neutropenia, including agranulocytosis.
Pokazano je da deferipron uzrokuje neutropeniju, uključujući agranulocitozu.
One pack contains 100 film-coated tablets.
Jedno pakiranje sadrži 100 filmom obloženih tableta.
Deferiprone Lipomed in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction (see section 4.2).
Deferipron Lipomed u kombinaciji s drugim kelatorom (vidjeti dio 4.4.) indiciran je kod bolesnika s talasemijom major kada je monoterapija s bilo kojim kelatorom željeza neučinkovita ili kada prevencija ili liječenje posljedica preopterećenja željezom opasnih po život opravdava brzu ili intenzivnu korekciju (vidjeti dio 4.2).
Plasma Zn2+ concentration Monitoring of plasma Zn2+ concentration, and supplementation in case of a deficiency, is recommended.
Preporučuje se praćenje koncentracije Zn2+ u plazmi i u slučaju deficita njegova nadoknada.
Fertility No effects on fertility or early embryonic development were noted in animals (see section 5.3).
Plodnost Nisu primijećeni učinci na plodnost ili rani embrionalni razvoj u životinja (vidjeti dio 5.3).
The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count (ANC) is less than 1.5 x 109/l.
Rizik od agranulocitoze i neutropenije je viši ako su početne vrijednosti apsolutnog broja neutrofila (ABN) manje od 1,5 x 109/l.
The effect of Deferiprone Lipomed in decreasing the body iron is directly influenced by the dose and the degree of iron overload.
Učinak lijeka Deferipron Lipomed na snižavanje razine željeza u tijelu izravno je ovisan o dozi i stupnju preopterećenja željezom.
Data from the published literature on iron balance studies in patients with thalassaemia major show that the use of deferiprone concurrently with deferoxamine (co-administration of both chelators during the same day, either simultaneously or sequentially, e.g., deferiprone during the day and deferoxamine during the night), promotes greater iron excretion than either drug alone.
Podatci iz objavljene literature o ispitivanjima ravnoteže željeza kod bolesnika s talasemijom major pokazuju da primjena deferiprona istodobno s deferoksaminom (istodobna primjena oba kelatora istog dana, bilo simultano ili jedan iza drugog, npr. deferipron tijekom dana a deferoksamin tijekom noći) potiče veće izlučivanje željeza nego bilo koji od lijekova primijenjen samostalno.
If you take more Deferiprone Lipomed than you should There are no reports of acute overdose with deferiprone.
Ako uzmete više lijeka Deferipron Lipomed nego što ste trebali Nema prijava o akutnom predoziranju deferipronom.
After starting Deferiprone Lipomed therapy, it is recommended that serum ferritin concentrations, or other indicators of body iron load, be monitored every two to three months to assess the long-term effectiveness of the chelation regimen in controlling the body iron load.
Nakon započinjanja terapije lijekom Deferipron Lipomed preporučuje se praćenje koncentracija feritina u serumu, ili drugih pokazatelja opterećenja tijela željezom, svaka dva do tri mjeseca, radi procjene dugotrajne učinkovitosti režima kelacije u svrhu kontrole opterećenja tijela željezom.
Prescribers are reminded that the use of doses above 100 mg/kg/day is not recommended.
Podsjećamo liječnike koji propisuju ovaj lijek da se primjena doza iznad 100 mg/kg/dan ne preporučuje.
In the event of agranulocytosis, re-challenge is contraindicated.
U slučaju agranulocitoze ponovna primjena lijeka je kontraindicirana.
The patient's neutrophil count should be monitored every week.
Bolesniku se mora kontrolirati broj neutrofila svaki tjedan.
Episodes of hypotonia, instability, inability to walk, and hypertonia with inability of limb movement have been reported in children in the post-marketing setting with standard doses of deferiprone.
Epizode hipotonije, nestabilnosti, nemogućnosti hodanja te hipertonije s nemogućnošću pokretanja udova prijavljene su kod djece u periodu nakon stavljanja lijeka u promet sa standardnim dozama deferiprona.
Other medicines and Deferiprone Lipomed
Drugi lijekovi i Deferipron Lipomed
Clinical studies have demonstrated that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia.
Klinička ispitivanja pokazala su da je deferipron učinkovit u poboljšanju izlučivanja željeza, i da u dozi od 25 mg/kg tri puta na dan može spriječiti progresiju akumulacije željeza, a što je dokazivo mjerenjem feritina u serumu, u bolesnika s talasemijom ovisnom o transfuziji.
Please refer to the patient/carer reminder card provided in the folding box.
Molimo pogledajte u karticu s podsjetnikom za bolesnika/njegovatelja koja se nalazi u sklopivoj kutiji.
In these patients careful monitoring of liver histology is recommended.
U ovih se bolesnika preporučuje pažljivo praćenje histoloških promjena u jetri.
What you need to know before you take Deferiprone Lipomed
Što morate znati prije nego uzmete Deferipron Lipomed
Deferiprone Lipomed contains sodium
Deferipron Lipomed sadrži natrij
This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken deferiprone in clinical studies.
Ovo stanje, poznato kao teška neutropenija ili agranulocitoza, javilo se u 1 do 2 na 100 ljudi koji su uzimali deferipron u kliničkim ispitivanjima.
If you forget to take Deferiprone Lipomed
Ako ste zaboravili uzeti Deferipron Lipomed
Common side effects (may affect up to 1 in 10 people): - low white blood cell count (agranulocytosis and neutropenia) - headache - diarrhoea - increase in liver enzymes - fatigue - increase in appetite
Česte nuspojave (mogu se pojaviti kod do 1 na 10 ljudi): - nizak broj leukocita (agranulocitoza i neutropenija) - glavobolja - proljev - porast jetrenih enzima - umor - povećan apetit
((Back Cover))
((Stražnja strana pakiranja))
Subjects were categorized into 4 groups based on estimated glomerular filtration rate (eGFR): healthy volunteers (eGFR ≥ 90 mL/min/1.73m2), mild renal impairment (eGFR 60-89 mL/min/1.73m2), moderate renal impairment (eGFR 30-59 mL/min/1.73m2), and severe renal impairment (eGFR 15-29 mL/min/1.73m2).
Ispitanici su na temelju procijenjene brzine glomerularne filtracije (eGFR) bili podijeljeni u 4 skupine: zdravi dobrovoljci (eGFR ≥ 90 ml/min/1,73 m2), ispitanici s blagim oštećenjem funkcije bubrega (eGFR 60-89 ml/min/1,73 m2), ispitanici s umjerenim oštećenjem funkcije bubrega (eGFR 30-59 ml/min/1,73 m2) i ispitanici s teškim oštećenjem funkcije bubrega (eGFR 15-29 ml/min/1,73 m2).
The higher rate of “Cardiac disorders” reported during combination therapy than monotherapy was possibly due to the higher incidence of pre-existing cardiac disorders in patients who received combination therapy.
Veća stopa „srčanih poremećaja” prijavljenih za vrijeme kombinirane terapije nego za vrijeme monoterapije je možda uzrokovana većom incidencijom postojećih srčanih poremećaja kod bolesnika koji su primali kombiniranu terapiju.
What Deferiprone Lipomed looks like and contents of the pack Deferiprone Lipomed 500 mg film-coated tablets are white to off-white, glossy surface, oval filmcoated tablets.
Kako Deferipron Lipomed izgleda i sadržaj pakiranja Tablete Deferipron Lipomed od 500 mg bijele su do bjelkaste boje, filmom obložene tablete ovalnog oblika i sjajne površine.
Deferiprone use should be discontinued if neurological disorders are observed (see sections 4.8 and 4.9).
Treba prekinuti primjenu deferiprona ako se opaze neurološki poremećaji (vidjeti dijelove 4.8 i 4.9).
Coating: hypromellose, macrogol 6000, titanium dioxide
Ovojnica: hipromeloza, makrogol 6000, titanijev dioksid.
To monitor for neutropenia, your doctor will ask you to have a blood test (to check your white blood cell count) performed regularly, as frequently as every week, while you are being treated with Deferiprone Lipomed.
Vaš će liječnik od Vas tražiti da redovito činite krvne pretrage (radi provjere broja bijelih krvnih stanica), svakog tjedna, za sve vrijeme dok se liječite lijekom Deferipron Lipomed.
The most common findings in non-iron-loaded animals at doses of 100 mg/kg/day and above were hematologic effects such as bone marrow hypocellularity, and decreased WBC, RBC and/or platelet counts in peripheral blood.
Najčešći nalazi u željezom neopterećenih životinja pri dozama od 100 mg/kg/dan i više bili su hematološki učinci poput hipocelularnosti koštane srži i pada broja leukocita, eritrocita i/ili trombocita u perifernoj krvi.
In clinical trials, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis and those episodes resolved once therapy was withdrawn.
U kliničkim ispitivanjima tjedno praćenje broja neutrofila bilo je učinkovito u prepoznavanju slučajeva neutropenije i agranulocitoze koje su se povukle nakon što je liječenje prekinuto.
The most serious adverse reaction reported in clinical trials with deferiprone was agranulocytosis, defined as an absolute neutrophil count less than 0.5 x 109/l, which occurred in approximately 1% of patients.
Najozbiljnija nuspojava prijavljena u kliničkim ispitivanjima s deferipronom bila je agranulocitoza, definirana kao apsolutni broj neutrofila manji od 0,5 x 109/l, što se dogodilo kod otprilike 1% bolesnika.
• To increase patient awareness of the significance of any symptoms of infection while taking Deferiprone Lipomed
• podizanje razine osviještenosti bolesnika o bilo kakvim simptomima infekcije prilikom primjene lijeka Deferipron Lipomed
HIV positive or other immunocompromised patients No data are available on the use of deferiprone in HIV positive or other immunocompromised patients.
Nema dostupnih podataka o primjeni deferiprona u HIV pozitivnih ili drugih imunokompromitiranih bolesnika.
The MAH shall ensure that in each Member State where Deferiprone Lipomed is marketed, all patients/carers who are expected to use Deferiprone Lipomed are provided with the Patient/Carer reminder card as a part of the outer packaging.
Nositelj odobrenja u svakoj državi članici u kojoj se Deferipron Lipomed stavlja u promet mora osigurati karticu s podsjetnikom u sklopu vanjskog pakiranja za svakog bolesnika/njegovatelja za koje se očekuje primjena lijeka Deferipron Lipomed.
The most serious side effect that may occur while taking Deferiprone Lipomed is a very low white blood cell (neutrophil) count.
Najozbiljnija nuspojava koja se može dogoditi dok uzimate Deferipron Lipomed je vrlo nizak broj bijelih krvnih stanica (neutrofila).
Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight.
Deferipron se obično daje u dozi od 25 mg/kg tjelesne težine, peroralno, tri puta na dan, do ukupne dnevne doze od 75 mg/kg tjelesne težine.
The incidences of “Musculoskeletal and connective tissue disorders” and “Renal and urinary disorders” were lower during combination therapy than monotherapy, whereas the incidence of “Cardiac disorders” was higher during combination therapy than monotherapy.
Incidencije „poremećaja mišićno-koštanog sustava i vezivnog tkiva” te „poremećaja bubrega i mokraćnog sustava” bile su manje za vrijeme kombinirane terapije nego za vrijeme monoterapije, dok je incidencija „srčanih poremećaja” bila veća za vrijeme kombinirane terapije nego za vrijeme monoterapije.
• Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5).
• zbog nepoznatog mehanizma nastanka neutropenije izazvane deferipronom, bolesnici ne smiju uzimati lijekove za koje je poznato da su povezani s neutropenijom ili lijekove koji mogu uzrokovati agranulocitozu (vidjeti dio 4.5).
Deferiprone was teratogenic and embryotoxic in reproductive studies in non-iron-loaded pregnant rats and rabbits at doses at least as low as 25 mg/kg/day.
U reproduktivnim ispitivanjima deferipron je bio teratogen i embriotoksičan u željezom neopterećenih skotnih ženki štakora i kunića u dozama niskim najmanje od 25 mg/kg/dan.
- Provided in the folding box, you will find a patient/carer reminder card. You should complete and read the card carefully and carry it with you.
Karticu trebate ispuniti i pažljivo pročitati i nositi sa sobom.
What Deferiprone Lipomed is and what it is used for 2.
Što je Deferipron Lipomed i za što se koristi
This medicine contains less than 1 mmol sodium (23 mg) per tablet and that is to say essentially ‘sodium-free'.
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tableti, tj. zanemarive količine natrija.
UNIQUE IDENTIFIER - HUMAN READABLE DATA
JEDINSTVENI IDENTIFIKATOR - PODATCI ČITLJIVI LJUDSKIM OKOM PC:
For women of child bearing age
Za žene reproduktivne dobi
INFORMATION IN BRAILLE Deferiprone Lipomed 500 mg
16. PODATCI NA BRAILLEOVOM PISMU Deferipron Lipomed 500 mg
Important Safety Reminders for Patients Taking Deferiprone Lipomed Prescribing doctor:________________________ Phone no:_______________________________
Liječnik koji je propisao lijek:________________________
Based on the results of this study, no adjustment of the deferiprone dosage regimen is required in patients with impaired renal function.
Na temelju rezultata ovog ispitivanja, nije potrebna prilagodba režima doziranja deferiprona u bolesnika s oštećenjem funkcije bubrega.
79576 Weil am Rhein Germany
79576 Weil am Rhein Njemačka
Atrophy of the thymus, lymphoid tissues, and testis, and hypertrophy of the adrenals, were reported at doses of 100 mg/kg/day or greater in non-iron-loaded animals.
Atrofija timusa, limfoidnog tkiva i testisa, te hipertrofija nadbubrežnih žlijezda prijavljeni su pri dozama od 100 mg/kg/dan ili višim u životinja neopterećenih željezom.
Concurrent use of iron chelators is not recommended in patients whose serum ferritin falls below 500 µg/l due to the risk of excessive iron removal.
Istodobna primjena kelatora željeza se ne preporučuje kod bolesnika čiji serumski feritin padne ispod 500 µg/l radi rizika od prekomjernog uklanjanja željeza.
Marketing Authorisation Holder and Manufacturer Lipomed GmbH
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač Lipomed GmbH
Based on the results of this study, no adjustment of the deferiprone dosage regimen is required in patients with mildly or moderately impaired hepatic function.
Na temelju rezultata ovog ispitivanja, nije potrebna prilagodba režima doziranja deferiprona u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre.
The most serious side effect of Deferiprone Lipomed is a very low white blood cell (neutrophil) count.
Najozbiljnija nuspojava lijeka Deferipron Lipomed je vrlo nizak broj bijelih krvnih stanica (neutrofila).
The most serious adverse reaction reported in clinical trials with deferiprone is agranulocytosis (neutrophils <0.5 x 109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4).
Najozbiljnija nuspojava prijavljena u kliničkim ispitivanjima s deferipronom je agranulocitoza (neutrofili <0,5 x 109/l), s incidencijom od 1,1% (0,6 slučajeva na 100 bolesnik-godina liječenja) (vidjeti dio 4.4).
Very common side effects (may affect more than 1 in 10 people): - abdominal pain - nausea - vomiting - reddish/brown discoloration of urine
Vrlo česte nuspojave (mogu se pojaviti kod više od 1 na 10 ljudi): - bol u trbuhu - mučnina - povraćanje - crvenkasto/smeđa boja mokraće
Deferiprone Lipomed is used to treat iron overload caused by frequent blood transfusions in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Deferipron Lipomed se koristi se za liječenje preopterećenja željezom uzrokovanog čestim transfuzijama krvi u bolesnika s talasemijom major kada je trenutna kelacijska terapija kontraindicirana ili neodgovarajuća.
Do not take aluminium-based antacids at the same time as taking Deferiprone Lipomed.
Nemojte uzimati antacide na bazi aluminija za vrijeme liječenja lijekom Deferipron Lipomed.
Do not take Deferiprone Lipomed if you are pregnant or if you are trying to become pregnant.
Nemojte uzimati lijek Deferipron Lipomed ako ste trudni ili nastojite zatrudnjeti.
Tablet core: hypromellose, croscarmellose sodium, silica, colloidal anhydrous, microcrystalline cellulose, magnesium stearate
Jezgra tablete: hipromeloza, umrežena karmelozanatrij, silicijev dioksid, bezvodni, mikrokristalična celuloza, magnezijev stearat.
You must use effective contraception while you are taking Deferiprone Lipomed.
Dok uzimate Deferipron Lipomed morate koristiti učinkovitu kontracepciju.
Monitoring your white blood cell count with Deferiprone Lipomed
Praćenje krvne slike bijelih krvnih stanica prilikom uzimanja lijeka Deferipron Lipomed
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg deferiprone.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadrži 500 mg deferiprona.
What Deferiprone Lipomed contains The active substance is deferiprone.
Što Deferipron Lipomed sadrži Djelatna tvar je deferipron.
An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired renal function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of deferiprone.
Provedeno je otvoreno, nerandomizirano kliničko ispitivanje s paralelnim skupinama kako bi se procijenio učinak oštećenja funkcije bubrega na sigurnost, podnošljivost i farmakokinetiku jedne peroralne doze deferiprona od 33 mg/kg.
• To increase patient awareness of the importance of regular monitoring of the neutrophil count during treatment with Deferiprone Lipomed
• podizanje razine osviještenosti bolesnika o važnosti redovitog praćenja broja neutrofila tijekom liječenja lijekom Deferipron Lipomed
• History of recurrent episodes of neutropenia.
• rekurentne epizode neutropenije u anamnezi.
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Monoterapija lijekom Deferipron Lipomed indicirana je za liječenje preopterećenja željezom u bolesnika s talasemijom major kada je trenutna kelacijska terapija kontraindicirana ili neodgovarajuća.
• History of agranulocytosis.
• agranulocitoza u anamnezi.
NAME OF THE MARKETING AUTHORISATION HOLDER Lipomed GmbH
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Lipomed GmbH
In post-marketing experience with deferiprone, neurological disorders (such as tremors, walking disorders, double vision, involuntary muscle contractions, problems with movement coordination) have been reported in children who had been voluntarily prescribed more than double the maximum recommended dose of 100 mg/kg/day for several years.
Nakon stavljanja lijeka u promet, kod deferiprona su zabilježeni neurološki poremećaji (kao što je nevoljno drhtanje, poremećaji hodanja, dvoslika, nevoljno grčenje mišića, problemi s koordinacijom pokreta) prijavljeni su kod djece kojoj je dobrovoljno propisivana više od dvostruko puta veća doza od maksimalno preporučene doze od 100 mg/kg/dan tijekom nekoliko godina.
Patients should be advised to report immediately to their physician any symptoms indicative of infection such as fever, sore throat or flu-like symptoms.
Bolesnicima treba savjetovati da odmah jave svom liječniku bilo koje simptome koji mogu upućivati na infekciju, poput vrućice, grlobolje ili simptoma nalik gripi.
Phone number: +49 7621 1693 472
Telefaks: +49 7621 1693 474
Renal and hepatic function should be monitored in these patient populations during deferiprone therapy.
Tijekom terapije deferipronom potrebno je pratiti funkciju bubrega i jetre u ovim populacijama bolesnika.
Each 500 mg film-coated tablet contains 500 mg deferiprone.
Jedna filmom obložena tableta od 500 mg sadrži 500 mg deferiprona.
Dose table for Deferiprone Lipomed 500 mg film-coated tablets Body weight (kg)
Tablica doziranja za Deferipron Lipomed 500 mg filmom obložene tablete Tjelesna težina (kg)
• Breast-feeding (see section 4.6).
• dojenje (vidjeti dio 4.6).
Phone number: +49 7621 1693 472 Fax number: +49 7621 1693 474 lipomed@lipomed.com
Tel.: +49 7621 1693 472 Telefaks: +49 7621 1693 474 lipomed@lipomed.com
Croscarmellose sodium Silica, colloidal anhydrous Microcrystalline cellulose Magnesium stearate
Jezgra tablete hipromeloza karmelozanatrij, umrežena silicijev dioksid, koloidni, bezvodni celuloza, mikrokristalična magnezijev stearat
Abdominal pain Vomiting
Poremećaji probavnog sustava mučnina bol u abdomenu povraćanje proljev
Dose adjustment is not required in patients with mild, moderate, or severe renal impairment (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s blagim, umjerenim ili teškim oštećenjem funkcije bubrega (vidjeti dio 5.2).
Phone number: +49 7621 1693 472 Fax number: +49 7621 1693 474 Electronic mail: lipomed@lipomed.com
Telefaks: +49 7621 1693 474 E-pošta: lipomed@lipomed.com
How to take Deferiprone Lipomed
Kako uzimati Deferipron Lipomed
How to store Deferiprone Lipomed
Kako čuvati Deferipron Lipomed
Report immediately to your doctor any symptoms of infection such as fever, sore throat or flu-like symptoms.
Odmah prijavite svom liječniku bilo koje simptome infekcije, poput vrućice, grlobolje ili simptoma nalik gripi.
Do not take Deferiprone Lipomed if you are breast-feeding.
Ne uzimajte Deferipron Lipomed ako dojite.
White to off-white, glossy surface, oval film-coated tablet.
Bijela do bjelkasta filmom obložena tableta ovalnog oblika i sjajne površine.
Deferiprone Lipomed 500 mg film-coated tablets deferiprone
Deferipron Lipomed 500 mg filmom obložene tablete deferipron